Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 31.30
ARWR's Cash to Debt is ranked lower than
51% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. ARWR: 31.30 )
Ranked among companies with meaningful Cash to Debt only.
ARWR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 13.55 Max: No Debt
Current: 31.3
Equity to Asset 0.75
ARWR's Equity to Asset is ranked higher than
59% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARWR: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
ARWR' s Equity to Asset Range Over the Past 10 Years
Min: -32.54  Med: 0.73 Max: 0.91
Current: 0.75
-32.54
0.91
Interest Coverage N/A
ARWR's Interest Coverage is ranked lower than
55% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ARWR: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARWR' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 1
Z-Score: -3.03
M-Score: -4.11
WACC vs ROIC
6.93%
-570.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -51410.06
ARWR's Operating margin (%) is ranked lower than
98% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. ARWR: -51410.06 )
Ranked among companies with meaningful Operating margin (%) only.
ARWR' s Operating margin (%) Range Over the Past 10 Years
Min: -51736.08  Med: -8478.97 Max: -520.49
Current: -51410.06
-51736.08
-520.49
Net-margin (%) -51398.11
ARWR's Net-margin (%) is ranked lower than
98% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. ARWR: -51398.11 )
Ranked among companies with meaningful Net-margin (%) only.
ARWR' s Net-margin (%) Range Over the Past 10 Years
Min: -51723.42  Med: -10738.97 Max: -513.78
Current: -51398.11
-51723.42
-513.78
ROE (%) -94.34
ARWR's ROE (%) is ranked lower than
79% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. ARWR: -94.34 )
Ranked among companies with meaningful ROE (%) only.
ARWR' s ROE (%) Range Over the Past 10 Years
Min: -225.02  Med: -94.07 Max: -28.66
Current: -94.34
-225.02
-28.66
ROA (%) -74.03
ARWR's ROA (%) is ranked lower than
80% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. ARWR: -74.03 )
Ranked among companies with meaningful ROA (%) only.
ARWR' s ROA (%) Range Over the Past 10 Years
Min: -154.73  Med: -77.87 Max: -22.16
Current: -74.03
-154.73
-22.16
ROC (Joel Greenblatt) (%) -991.12
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. ARWR: -991.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARWR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11843.37  Med: -1977.04 Max: -584.83
Current: -991.12
-11843.37
-584.83
Revenue Growth (3Y)(%) -37.00
ARWR's Revenue Growth (3Y)(%) is ranked lower than
83% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARWR: -37.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARWR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -51.5 Max: 64.8
Current: -37
0
64.8
EBITDA Growth (3Y)(%) 10.50
ARWR's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. ARWR: 10.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARWR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: -12.5 Max: 190.2
Current: 10.5
-56.2
190.2
EPS Growth (3Y)(%) 1.10
ARWR's EPS Growth (3Y)(%) is ranked higher than
55% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ARWR: 1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARWR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.1  Med: -7.3 Max: 162.1
Current: 1.1
-75.1
162.1
GuruFocus has detected 2 Warning Signs with Arrowhead Pharmaceuticals Inc $ARWR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ARWR Guru Trades in Q4 2015

Paul Tudor Jones 41,313 sh (+136.79%)
» More
Q1 2016

ARWR Guru Trades in Q1 2016

Paul Tudor Jones Sold Out
» More
Q2 2016

ARWR Guru Trades in Q2 2016

Steven Cohen 256,101 sh (New)
» More
Q3 2016

ARWR Guru Trades in Q3 2016

Steven Cohen 8,500 sh (-96.68%)
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2835
Compare:NAS:ENZY, OTCPK:RCAR, NAS:QURE, OTCPK:BBLG, NAS:XENE, OTCPK:RNUGF, NAS:EGLT, NAS:VTL, NAS:IMDZ, NAS:CTIC, OTCPK:HSDT, OTCPK:CTIX, NAS:NVIV, OTCPK:PAIOF, NAS:GLYC, NAS:NYMX, OTCPK:PRMCF, NAS:AVXL, NAS:REPH, OTCPK:HPPI » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.

Arrowhead Pharmaceuticals Inc, formerly Arrowhead Research Corp was originally incorporated in South Dakota in the year 1989, and was reincorporated in Delaware in 2000. The Company is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. Its products include ARC-520, Adipotide. The Company controls 306 patents. The Company and its products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the FDCA), and other laws within the Public Health Service Act.

Ratios

vs
industry
vs
history
P/B 1.29
ARWR's P/B is ranked higher than
82% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. ARWR: 1.29 )
Ranked among companies with meaningful P/B only.
ARWR' s P/B Range Over the Past 10 Years
Min: 0.91  Med: 4.78 Max: 71.58
Current: 1.29
0.91
71.58
P/S 443.57
ARWR's P/S is ranked lower than
94% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. ARWR: 443.57 )
Ranked among companies with meaningful P/S only.
ARWR' s P/S Range Over the Past 10 Years
Min: 4.04  Med: 200 Max: 4132.5
Current: 443.57
4.04
4132.5
Current Ratio 3.53
ARWR's Current Ratio is ranked lower than
56% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ARWR: 3.53 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.07 Max: 22.28
Current: 3.53
0.01
22.28
Quick Ratio 3.53
ARWR's Quick Ratio is ranked lower than
54% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ARWR: 3.53 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.53 Max: 22.28
Current: 3.53
0.01
22.28
Days Sales Outstanding 172.17
ARWR's Days Sales Outstanding is ranked lower than
87% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. ARWR: 172.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARWR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.12  Med: 82.79 Max: 1982.84
Current: 172.17
1.12
1982.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.00
ARWR's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. ARWR: -29.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARWR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -598.6  Med: -29 Max: 0
Current: -29
-598.6
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.42
ARWR's Price/Net Cash is ranked higher than
79% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. ARWR: 2.42 )
Ranked among companies with meaningful Price/Net Cash only.
ARWR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.05  Med: 7.86 Max: 21.43
Current: 2.42
0.05
21.43
Price/Net Current Asset Value 2.22
ARWR's Price/Net Current Asset Value is ranked higher than
80% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ARWR: 2.22 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARWR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.04  Med: 7.39 Max: 15.67
Current: 2.22
0.04
15.67
Price/Tangible Book 1.75
ARWR's Price/Tangible Book is ranked higher than
78% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ARWR: 1.75 )
Ranked among companies with meaningful Price/Tangible Book only.
ARWR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.04  Med: 6.64 Max: 15.01
Current: 1.75
0.04
15.01
Price/Median PS Value 2.30
ARWR's Price/Median PS Value is ranked lower than
88% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ARWR: 2.30 )
Ranked among companies with meaningful Price/Median PS Value only.
ARWR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.63 Max: 18.46
Current: 2.3
0.04
18.46
Earnings Yield (Greenblatt) (%) -293.40
ARWR's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ARWR: -293.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARWR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1217.63  Med: 0 Max: 1793.66
Current: -293.4
-1217.63
1793.66

More Statistics

Revenue (TTM) (Mil) $0.16
EPS (TTM) $ -1.33
Beta0.62
Short Percentage of Float16.05%
52-Week Range $1.20 - 8.22
Shares Outstanding (Mil)74.17

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 0 0
EPS ($) -0.81 -0.73
EPS w/o NRI ($) -0.81 -0.73
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
IMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit... Jan 14 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead... Jan 13 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of... Jan 13 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Jan 12 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 12 2017
These 3 Biotech Stocks Are Already Moving Wildly on Thursday Jan 12 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Jan 10 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a... Jan 09 2017
Monday’s 4 Biggest Biopharma Movers Jan 09 2017
Arrowhead Provides Response to New Minority Shareholder Announcement Jan 09 2017
DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action... Jan 07 2017
ARWR LOSS NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important... Jan 06 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Jan 05 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 04 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Jan 03 2017
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : January 3, 2017 Jan 03 2017
ARWR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action... Jan 03 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Dec 28 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Dec 28 2016
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Dec 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)